New study aims to find best first immunotherapy for advanced liver cancer

NCT ID NCT07147101

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers will track how well different drug combinations shrink tumors and how the immune system changes. The goal is to learn which treatments work best and why, without assigning participants to a specific therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunotherapy drugs (sintilimab, camrelizumab, nivolumab, ipilimumab, bevacizumab biosimilar, rivoceranib)
What this could lead to: If successful, this could help identify which immunotherapy combinations work best for advanced liver cancer, potentially improving treatment choices.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. The sample size is small (150 people), and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.